Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Voyageur Pharmaceuticals ( (TSE:VM) ) just unveiled an update.
Voyageur Pharmaceuticals has received a $600,000 grant from Alberta Innovates to support the commercialization of its Frances Creek barium sulfate, emphasizing its advantages over synthetic alternatives. The grant will assist in enhancing product quality, addressing supply shortages, and strengthening Voyageur’s market position as they prepare to launch their licensed products, which are expected to improve patient outcomes and ensure long-term shareholder value.
More about Voyageur Pharmaceuticals
Voyageur Pharmaceuticals Ltd. operates within the health technology industry, focusing on the development and commercialization of barium-based contrast products. The company aims to address supply shortages and enhance diagnostic imaging standards using natural resources from Canada.
YTD Price Performance: 0.0%
Average Trading Volume: 56,856
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $20.16M
For detailed information about VM stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue